HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. - Abstract - Europe PMC
Histone Deacetylase Inhibitors in Multiple Myeloma | SpringerLink
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaem
Cytarabine (Cytosine β-D-arabinofuranoside) | DNA Synthesis Inhibitor | MedChemExpress
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
V_Hematology_Forum_Prof_Lowenberg
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram
Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Cytarabine - Wikipedia
3942-Consolidation HiDAC (cytarabine) 1,2,3 | eviQ
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine
HDAC - high-dose ara-C
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect
